^
2d
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (clinicaltrials.gov)
P1, N=30, Recruiting, Bio-Path Holdings, Inc. | Trial completion date: Jan 2025 --> Jan 2026
Trial completion date
|
BCL2 expression
|
liposomal Bcl2 (BP1002)
3d
Trial completion
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
Promune (agatolimod)
4d
P30CA033572: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • daunorubicin
4d
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (clinicaltrials.gov)
P1, N=20, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=30 --> 20
Enrollment closed • Enrollment change
|
TNFRSF8 positive
|
lenalidomide • Istodax (romidepsin) • Onureg (azacitidine oral)
4d
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) (clinicaltrials.gov)
P2, N=28, Recruiting, Deepa Jagadeesh | Trial completion date: Dec 2023 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
Adcetris (brentuximab vedotin)
7d
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab (clinicaltrials.gov)
P2, N=25, Recruiting, Ohio State University Comprehensive Cancer Center | Trial primary completion date: Dec 2023 --> Dec 2024
Trial primary completion date
|
Campath (alemtuzumab)
7d
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (clinicaltrials.gov)
P1/2, N=13, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive • ALK negative
|
Keytruda (pembrolizumab) • Folotyn (pralatrexate)
9d
Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. (PubMed, Cell Rep Med)
We also perform an unsupervised clustering on the microenvironment transcriptional signatures and categorize PTCL into 4 lymphoma microenvironment subtypes based on characteristic activation of oncogenic pathways and composition of immune communities. Our findings highlight the potential clinical rationale of future precision medicine strategies that target both molecular and microenvironment alterations in PTCL.
Journal
|
TET2 (Tet Methylcytosine Dioxygenase 2) • RHOA (Ras homolog family member A)
|
TET2 mutation
10d
Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy. (PubMed, Virchows Arch)
In conclusion, 44% of ALCL patients, regardless of histological subtypes, showed a loss of/decrease in CD30 expression after receiving BV-containing therapy, but this phenomenon was not observed in CHL patients. A higher cumulative dose of BV and a lower amount of CD30 antigen in tumor cells in the initial biopsy materials might be predictors of a loss of/decrease in CD30 expression in ALCL patients.
Journal
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • TNFRSF8 expression • ALK negative
|
Adcetris (brentuximab vedotin)
11d
New P1 trial
|
SGN-35C
16d
REALM: A Study of People With CD30 Positive Lymphoma in China (clinicaltrials.gov)
P=N/A, N=2800, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting
Enrollment closed
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
17d
PROSECO: Immune Responses to COVID-19 Vaccination in Lymphoma Patients (clinicaltrials.gov)
P=N/A, N=592, Completed, University Hospital Southampton NHS Foundation Trust | Active, not recruiting --> Completed
Trial completion
21d
Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). (PubMed, Blood)
These entities are currently treated similarly with CHOP or CHOEP for CD30-negative diseases or brentuximab vedotin plus CHP for CD30-positive diseases, followed by consolidation with autologous stem cell transplant in first remission...Although current treatment strategies lump most disease entities together, future treatment will include distinct strategies for each disease subtype that optimizes therapy for individuals. This movement towards individualized therapy will ultimately lead to dramatic improvements in prognosis for patients with PTCL.
Journal
|
EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 negative
|
Adcetris (brentuximab vedotin)
21d
Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management. (PubMed, Am J Hematol)
This includes the CD30 directed antibody drug conjugate brentuximab vedotin...The use of checkpoint inhibitors in the treatment of PTCL is still controversial, with best results seen in cases of extranodal natural killer cell/T-cell lymphoma. Bispecific antibody-based treatments and chimeric antigen receptor cell-based therapies are in clinical trials.
Review • Journal
|
ALK (Anaplastic lymphoma kinase) • IL2RA (Interleukin 2 receptor, alpha)
|
Adcetris (brentuximab vedotin)
21d
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
acimtamig (AFM13)
22d
FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis. (PubMed, Clin Exp Med)
FLI-1 expression can lead to diagnostic confusion, especially in small blue round cell tumors, such as lymphoblastic lymphoma, plasmablastic lymphoma, and plasma cell myeloma, when distinguishing tumors positive for CD99 and CD56 without CD3, CD20, or CD45. Our findings also suggested the possibility of FLI-1 as a potential prognostic biomarker for plasmablastic lymphoma.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD99 (CD99 Molecule)
22d
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma (clinicaltrials.gov)
P3, N=130, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
Epidaza (chidamide) • SHR-2554
23d
Trial completion
|
Copiktra (duvelisib)
24d
Allogeneic hematopoietic stem cell transplantation for mature T/NK-cell lymphomas in children. (PubMed, Transplant Cell Ther)
All patients received myeloablative conditioning based on treosulfan or total body irradiation (TBI). Non-relapse mortality was 5%, the cumulative incidence of relapse or progression at five years was 27%, five-year event-free survival was 67%, and 5-year overall survival was 78%. Thus, our data support that allogeneic αβ T-cell-depleted HSCT can provide long-term overall survival of children with high-risk mature T-cell lymphomas.
Journal
|
ALK (Anaplastic lymphoma kinase)
|
ALK positive
|
Ovastat (treosulfan)
1m
Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov)
P1, N=3, Terminated, Stanford University | Phase classification: P1/2 --> P1
Phase classification • Combination therapy
|
Yervoy (ipilimumab)
1m
A Global Study of the PETAL Consortium (clinicaltrials.gov)
P=N/A, N=1200, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
Enrollment open • Machine learning
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
1m
The prognostic significance of POD24 in peripheral T-cell lymphoma. (PubMed, Hematology)
Non response (NR) to treatment and POD24 were identified as independent negative prognostic factors for survival in patients with PTCL. POD24 is a prognostic factor associated with unfavorable outcomes in patients with PTCL and can be used to identify high-risk patients and guide treatment decisions.
Journal
|
B2M (Beta-2-microglobulin)
1m
KLRG1 Cell Depletion As A Novel Therapeutic Strategy In Patients With Mature T-cell lymphoma Subtypes. (PubMed, Clin Cancer Res)
Our findings suggest the potential benefit of a broader treatment strategy combining therapeutic antibodies with PI3Ki for the treatment of patients with mature T-cell and NK-cell neoplasms.
Journal
|
CD8 (cluster of differentiation 8) • NCAM1 (Neural cell adhesion molecule 1) • KLRG1 (Killer Cell Lectin Like Receptor G1) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
|
KLRG1 expression
|
Copiktra (duvelisib)
1m
Clinicopathological implications of immunohistochemical expression of TBX21, CXCR3, GATA3, CCR4, and TCF1 in nodal follicular helper T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified. (PubMed, J Pathol Transl Med)
The TBX21 subtype was more prevalent than the GATA3 subtype in AITL. The GATA3 subtype was associated with poor prognosis in patients with non-AITL and PTCL-NOS.
Journal • IO biomarker
|
CCR4 (C-C Motif Chemokine Receptor 4) • TBX21 (T-Box Transcription Factor 21) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • GATA3 (GATA binding protein 3)
1m
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression (clinicaltrials.gov)
P2, N=82, Active, not recruiting, Seagen Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
doxorubicin hydrochloride • cyclophosphamide • Adcetris (brentuximab vedotin) • prednisone
1m
SGNTGT-001: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer (clinicaltrials.gov)
P1, N=132, Terminated, Seagen Inc. | Trial completion date: Apr 2025 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Dec 2023; Study closed due to portfolio prioritization
Trial completion date • Trial termination • Trial primary completion date • Metastases
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
|
Adcetris (brentuximab vedotin) • sasanlimab (PF-06801591) • SEA-TGT
1m
Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients. (PubMed, Cancer Med)
The classification of PTCL-NOS into PTCL-TBX21 and PTCL-GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CD4 (CD4 Molecule) • TBX21 (T-Box Transcription Factor 21) • GATA3 (GATA binding protein 3)
|
CD4 positive
1m
Chi-GVM Regimen for the Treatment of R/R PTCL (clinicaltrials.gov)
P=N/A, N=50, Recruiting, The First Affiliated Hospital with Nanjing Medical University
New trial
|
gemcitabine • vinorelbine tartrate • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
1m
Trial completion
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Adcetris (brentuximab vedotin)
1m
Comparison of Follicular Helper T-Cell Markers with the Expression of the Follicular Homing Marker CXCR5 in Peripheral T-Cell Lymphomas-A Reappraisal of Follicular Helper T-Cell Lymphomas. (PubMed, Int J Mol Sci)
We found that CXCR5 is widely expressed in neoplastic TFH cells, except in TFHL-NOS, and represents a specific marker of this lymphoma entity. Our results suggest that CXCR5 directs the distribution of neoplastic T cells in the affected lymph nodes and may influence the formation of the pathognomic pathological FDC network.
Journal
|
CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
|
CXCR5 expression
1m
Relapsed/Refractory Peripheral T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis With UNC13D and CD27 Germline Mutations. (PubMed, Cell Transplant)
As of this report, the patient has remained free of lymphoma and quiescent HLH 15.2 months post-HSCT. This study underscores the efficacy of genetic tests in identifying significant mutations and confirming their etiologies, providing an early basis for treatment decisions and the selection of suitable transplant donors.
Journal • IO biomarker
|
NOTCH2 (Notch 2) • IL2RA (Interleukin 2 receptor, alpha) • NOTCH3 (Notch Receptor 3) • CD27 (CD27 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • TYK2 (Tyrosine Kinase 2) • UNC13D (Unc-13 Homolog D) • F13A1 (Coagulation Factor XIII A Chain)
1m
Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas. (PubMed, Leuk Res Rep)
The findings demonstrated decreased survival of T-cell lymphoma lines with both compounds. Overall, the results demonstrate that LAT1 is a valuable biomarker for aggressive T-cell lymphoma counterparts and QBS10072S and QBS10096S are successful therapeutic options for these aggressive diseases.
Journal
|
SLC7A5 (Solute Carrier Family 7 Member 5)
|
QBS72S
2ms
The gene expression profile and cell of origin of canine peripheral T-cell lymphoma. (PubMed, BMC Cancer)
Canine CD4+ PTCL most closely resembled the GATA3-PTCL subtype of PTCL-NOS and may originate from an earlier stage of T-cell development than the more conventionally posited mature T-helper cell origin.
Journal • Gene Expression Profile • IO biomarker
|
PTEN (Phosphatase and tensin homolog) • CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD34 (CD34 molecule) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • GATA3 (GATA binding protein 3) • HLA-DQB2 (Major Histocompatibility Complex, Class II, DQ Beta 2)
|
CD8 expression
2ms
THEORY: Genotype-guided Treatment in Newly Diagnosed PTCL (clinicaltrials.gov)
P1/2, N=264, Recruiting, Ruijin Hospital | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Jul 2028 | Trial primary completion date: Dec 2024 --> Jul 2026
Enrollment open • Trial completion date • Trial primary completion date
|
doxorubicin hydrochloride • Tevimbra (tislelizumab) • azacitidine • cyclophosphamide • Xpovio (selinexor) • Copiktra (duvelisib) • Epidaza (chidamide)
2ms
Homozygous Loss of CDKN2 in Primary Cutaneous CD8(+) Lymphoma NOS. (PubMed, Am J Dermatopathol)
Analyses of 4 cases of AL demonstrated often low p16 protein expression but intact CDKN2 loci. This case raises the problems of the boundaries between AL and PTCL NOS, and a possible role in the loss of p16 function in pathogenesis.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8)
|
CD8 positive
2ms
CD30 Imaging in Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P3, N=20, Not yet recruiting, University Medical Center Groningen
New P3 trial
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
Adcetris (brentuximab vedotin)
2ms
Trial completion date • Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule)
|
ALK positive • ALK negative
|
cyclophosphamide • MT-101
2ms
Trial completion date • Trial primary completion date • Combination therapy
|
Valcyte (valganciclovir) • nanatinostat (VRx-3996)
2ms
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (clinicaltrials.gov)
P2, N=20, Recruiting, UNC Lineberger Comprehensive Cancer Center
Trial completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
cyclophosphamide • fludarabine IV • TT11
2ms
Coincidence of de novo T-lymphoblastic lymphoma and cutaneous gamma/delta peripheral T-cell lymphoma. (PubMed, J Clin Exp Hematop)
After treating with reduced hyper-CVAD/MA targeting T-LBL, molecular complete remission was achieved. When an uncommon cutaneous lesion emerges in the course of T-ALL/LBL, both need to be evaluated pathologically and genetically, whether de novo or recurrent, assuming the possibility of coincident gamma/delta PTCL.
Journal
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • GZMB (Granzyme B) • CD99 (CD99 Molecule) • TRB (T Cell Receptor Beta Locus) • TRG (T Cell Receptor Gamma Locus)
2ms
A Safety Study of SGN-35T in Adults With Advanced Cancers (clinicaltrials.gov)
P1, N=110, Recruiting, Seagen Inc. | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
2ms
TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy. (PubMed, Am J Surg Pathol)
Chronic lymphocytic leukemia/small lymphocytic lymphoma and anaplastic large cell lymphoma demonstrated high TME TIGIT expression compared with PD-L1, with a high proportion of dual TIGIT and PD-L1-positivity. Our results are likely to contribute to the design and correlative study of therapeutic response in clinical trials targeting TIGIT alone or in combination with PD1/PDL1.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • PVR (PVR Cell Adhesion Molecule)
|
PD-L1 expression • TIGIT expression